Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRINTR: Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients
NCT05955924Phase 3Recruiting
- Sponsor
- Women's College Hospital
- Start
- Aug 2023
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in keratinocyte carcinoma comparing Nicotinamide with Placebo (2 arms). Primary endpoint: Time to first biopsy-confirmed keratinocyte carcinoma at 208 weeks. Started Aug 2023; status: recruiting.
02
Drugs
nicotinamide
03
Conditions
keratinocyte carcinoma
Beyond the preview
Go deeper on NCT05955924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05955924.